⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Figure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski Si-Qi Liu Lauren M. Zasadil Joseph L. Benci Patrick C. Gedeon Kendall J. Condon Suhasini Joshi Shana Posy Patrick Carlson Alison Maier Jiao Shen Rakeeb Kureshi Yuka Amako Tai Wang Ryan L. Powles Yanyun Li Tho Lai Igor Katsyv Hongchen Qiu Huilin Qi Jessica Wong Dandan Zhao Dana Banas Joelle M. Onorato Gregory Locke Xueer Chen Wen‐Chi Chou Erica Cook Abigail E. Witt Christopher M. Barbieri Hong Zhang Jonathan B. Olsen Alba Font‐Tello Eugene Drokhlyansky Denise C. Grünenfelder Louis Chupak Tyler A. Longmire Jon C. Jones Travis J. Hollmann David Kugler John N. Feder Raphael Bueno John C. Wain Pallavur Sivakumar Yu Liu Stephanie K. Dougan Cloud P. Paweletz David A. Barbie Emma Lees

View Full Paper

Ask AI

Bookmark

Share

Key Points

BMS-986408 significantly enhances PD-1 checkpoint and CAR T-cell immunotherapies.
Initial data shows improved effectiveness of BMS-986408 in combination with CAR T-cell therapy.
The approach utilizes a novel dual inhibition mechanism targeting DGKα and DGKζ.
These findings may lead to more effective cancer treatments and progress in immunotherapy strategies.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Discovery of BMS-986408 enhances PD-1 checkpoint and CAR T-cell immunotherapies, suggesting important implications.

Abstract

Fig. S7. Additional BMS-986408/CAR-T combination data.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wichroski et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f567 https://doi.org/10.1158/2326-6066.30029413

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
2Figure S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
3Figure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
4Figure S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
5Figure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025

Data from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
Supplementary Figure S2 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies2024
Supplementary Figure from Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain2023